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Background: Salivary glands (SGs) can be damaged by immune checkpoint inhibitor
(ICI) therapy. In patients with ICI-induced SG dysfunction, 60% progress to fulfill
classification criteria for primary Sjögren’s syndrome (pSS), owing to immune foci in SGs
and/or anti-SSA autoantibody positivity. We report the SG tissue analysis of a patient
with SG dysfunction after treatment with a programmed death ligand-1 (PD-L1) inhibitor,
compared to that of a dry mouth (“sicca”) control and pSS patient.
Case presentation: The patient received the PD-L1 inhibitor durvalumab (10 mg/kg,
every 2 weeks by intravenous infusion) as adjuvant treatment for stage 3 non-small cell
lung carcinoma, following concurrent chemo radiotherapy. At 43 weeks after 21 cycles
of Durvalumab, the patient was not capable of producing unstimulated or stimulated
parotid gland saliva, and a biopsy was taken. Immunohistochemical analysis showed
no classical AQP5+ CK7− acinar cell clusters (CK7 marks intercalated ducts, IDs). In
contrast, the parenchyma was dominated by hybrid epithelial “structures” with ID-like
morphology, containing a mixture of AQP5+CK7−, AQP5−CK7+, and AQP5+CK7+ cells
(30 structures/mm2). These structures were present at lower frequencies in sicca control
(2/mm2) and pSS (10/mm2) tissue. Hybrid structures contained proliferating (Ki67+)
cells and senescent (p16+) cells. Striated ducts showed no abnormal morphology
post PD-L1 treatment, in contrast to pSS tissue. PD-L1 expression was detected in
the SG parenchyma following anti-PD-L1 therapy. The SG post-PD-L1 therapy further
demonstrated focal lymphocytic sialadentitis, harboring disperse, and focal CD4+ T
cell-rich infiltrates. CD8+ T cells were also present. In this patient, these CD4+ and
CD8+ T cells were observed in-between and inside hybrid structures. CD20+ B-cells
were infrequently detected following PD-L1 blockade, in contrast to their preponderance
in pSS SG tissue.
Conclusion: This patient lacked conventional SG acinar cells following anti-PD-L1
therapy and demonstrated presence of hybrid intercalated duct-like structures.
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Understanding which mechanisms and dynamics underpinning this aberrant
parenchyma may be crucial to understand how SG dysfunction post ICI therapy,
and potentially other affected organs. Furthermore, although the patient treated with
anti-PD-L1 antibody examined here fulfills the criteria for pSS and demonstrated
focal lymphocytic sialadentitis, the further histopathological characteristics do not
resemble pSS.
Keywords: checkpoint inhibitors, anti PD-L1 therapy, salivary gland dysfunction, immune related adverse event,
cancer treatment, sicca syndrome, hyposalivation
BACKGROUND
Immune checkpoint inhibitor (ICI) therapy is the engagement of
the immune system to kill tumor cells via the blockade of immune
system inhibitory checkpoints, mostly employing cytotoxic T-
lymphocyte associated protein 4 (CTLA-4), programmed cell
death protein-1 (PD-1) and programmed death ligand-1 (PD-
L1). ICIs are efficacious in melanoma, lung cancer and head and
neck cancer treatment (1). In up to 60% of patients taking ICIs,
however, inflammatory diseases such as colitis, pneumonitis,
arthritis, inflammatory myopathy, vasculitis, nephritis and
sialadentitis, resembling primary Sjögren’s syndrome [pSS,
including salivary gland (SG) hypofunction] are observed (1–4).
“Sicca” syndrome arising from SG hypofunction, including dry
mouth, are reported at frequencies of 5% of all patients taking
ICIs (1–5).
In a healthy scenario, SG acinar cells produce and
secrete saliva, channeled through ducts into the mouth.
The vast majority of saliva is produced by the major (parotid,
submandibular, and sublingual) SGs, with small contributions
from the minor SGs located in the lips and oral cavity. SGs are
thought to be maintained by the proliferation and differentiation
of tissue resident progenitor cells, largely located in the
intercalated and striated ducts (6–9). The observation that
ICI-induced hyposalivation cannot be rescued by corticosteroid
treatment to dampen inflammation suggests that inflammation
is not causing SG hypofunction (3, 10, 11). The SG epithelium is
endowed with an ability to receive and transduce inflammatory
signals, and actively participate in inflammatory processes,
suggesting that a closer examination of the processes following
ICI use is crucial to our comprehension of this side-effect (12).
In the case presented here, we compare a parotid SG
following prolonged anti-PD-L1 therapy with a sicca control
parotid SG, and with a parotid SG from a patient with pSS,
to compare the effect of ICI treatment on the SG parenchyma.
pSS is an autoimmune disease characterized partly by SG
dysfunction, including lymphocytic infiltration, and the presence
of anti-SSA autoantibodies, resulting in hyposalivation and oral
dryness. SG lymphocytic infiltration in later stages of pSS is
predominantly B-cell based, and can also include presence of
germinal centers and lymphoepithelial lesions (LELs) (13, 14).
An increase in IgG plasma cells in the glands, resulting in <70%
IgA plasma cells, further characterizes pSS. Presence of anti-
SSA antibodies in blood, and/or a positive focus score (a read-
out of SG lymphocytic infiltration extent) plus reduced saliva
output leads to classification of our patient as suffering from
pSS [ACR-EULAR 2016 criteria (15)]. Studies have suggested
that ∼60% of patients treated with ICIs and experiencing dry
mouth complaints also demonstrate presence of SSA antibodies
and/or a positive focus score, designating them technically as
suffering from pSS (3, 5, 10, 11). The nature of the lymphocytic
infiltration following ICI therapy has been suggested to be CD4+
T cell dominated in the minor SGs (3, 5). That of the major
SGs and indeed the pathology of the parenchyma, responsible
for the majority of saliva production and secretion, has not
been documented.
CASE PRESENTATION
The patient (male, 52 years old) received the PD-L1 checkpoint
inhibitor durvalumab as an adjuvant treatment for stage
3b non-small cell lung carcinoma of the right upper lobe,
following chemo-radiotherapy. Durvalumab was administered
intravenously every 2 weeks at a dose of 10 mg/kg, as previously
published (16). The patient had a history of psoriasis. The patient
completed 1 year, 26 cycles of durvalumab. At cycle 11, he
presented clinically with a subjective sensation of dry mouth,
“sicca” complaints, and was not able to produce any unstimulated
or stimulated parotid saliva Additional clinical data is presented
in Table 1. Ultrasonography revealed moderate change in SG
topography (HOCEVAR score of 14/48), but remained under
the threshold score of 15/48 for a positive result (17–19). The
Schirmer’s test for ocular dryness was positive (4mm tear fluid
/5min), as opposed to the ocular staining score (OSS), which
was negative (0). In order to examine the pathology of the SG,
a parotid SG biopsy was performed following our previously
published protocol (20).
For comparison, parotid SG tissue from a sicca control
pSS patient were also analyzed. The sicca control patient
demonstrated reduced saliva production, negative HOCEVAR
score of 9/48, negative ocular dryness scores and no signs
of pSS development (Table 1). The patient with pSS was not
capable of producing unstimulated parotid saliva, produced
reduced volumes of stimulated parotid saliva (Table 1). The
patient with pSS also demonstrated SSA autoantibody positivity,
a positive ultrasound score (26/48), and positive test results
for ocular dryness (Table 1). All parotid salivary gland biopsies
were immunostained as previously reported, with CD45,
CD20, CD3, CD4, CD8, Ki67, IgA, IgG, Bcl6, high molecular
Frontiers in Oncology | www.frontiersin.org 2 April 2020 | Volume 10 | Article 420
Pringle et al. Lack of Acinar Cells With Anti-PD-L1 Therapy
TABLE 1 | Clinical characteristics of patients.
Characteristics Sicca control pSS Anti-PD-L1
Sex Female Female Male
Age 68 47 52
Unstimulated whole saliva (ml/min) ND 0.05 0
Stimulated whole saliva (ml/min) 1.35 0.37 0
Unstimulated parotid
saliva (ml/min)
Left 0 0 0
Right 0 0 0
Stimulated parotid saliva
(ml/min)
Left 0 0.09 0















Focus score (foci/4mm2 ) 0 2.5 1.0
Lymphoepithelial lesions (LELs) No Yes No
Germinal Center No Yes No
IgG plasma cells No No No
Ultrasound score –(9/48) +(26/48) –(14/48)
Ocular staining score (OSS) 0 3 0
Schirmer’s test (mm/5min) 6 0 4
ANA titre Neg 1:640 1:160
SSA − + +
ND, no data; ANA, anti-nuclear antibody; HC, healthy control. Ultrasound was scored
using the Hocevar et al. scoring system, as validated in Mossel et al., Annals Rheumatic
Diseases, 2017 (17). Ocular staining score (OSS) is considered positive for ocular dryness
with a score of >3 in at least one eye. Schirmer’s test is considered suggestive of
ocular dryness with <5mm tear fluid/5min in at least one eye. Serum levels of anti-SSA
antibodies were assessed with ELISA tests and scored as positive according to standard
procedures if more than 10 IU/mL.
weight cytokeratins, p16 and PD-L1 (all Ventana) (21).
Biopsies were additionally double immunostained for AQP5
and CK7, following antigen retrieval with EDTA buffer (pH
= 8) for 15min. A double staining kit containing secondary
antibodies from Thermofisher was used (TL-012-MARH).
Primary antibodies of AQP5 (Abcam, clone EPR3747, 1:200) and
CK7 (Sigma-Aldrich, clone RCK105, 1:100) were diluted in PBS.
Lack of Conventional Acinar Cells and
Skewing of the Epithelial Compartment
Toward Hybrid Intercalated Duct-Like
Structures
In order to examine the effect of anti-PD-L1 therapy on the
SG, we examined the striated ducts (SDs), intercalated ducts
(IDs) and acinar cells. The SDs of the SG in pSS can undergo
invasion by B cells, become proliferative and lead to formation of
LELs. The SDs of the sicca control patient demonstrated minimal
presence of Ki67+ proliferative cells (Figure 1a). Proliferative
epithelial cells, defined by immunostaining for Ki67 and high
molecular weight cytokeratins (hmwCK) in serial sections, were
detected in the pSS tissue (Figures 1b–d). No effect of anti-PD-
L1 therapy was apparent on SDs, which displayed a phenotype
similar to the sicca control and minimal proliferative cells,
marked by Ki67+ (Figures 1a,e).
In order to probe how durvalumab effects the acinar and
ID cell compartments, we immunostained tissue with AQP5
to mark acinar cells and CK7 to denote IDs. In healthy
conventional acinar cells, AQP5 is expressed at the apical
cell membrane, and CK7 is not heavily expressed. In sicca
control and pSS biopsies, clusters of AQP5+CK7− acinar cells
with large cytoplasm:nucleus ratios and are easily identifiable
(280/mm2 sicca control; 170/mm2 pSS; Figures 1f,g). AQP5
is localized apically in healthy acinar cell clusters (Figure 1f,
inset). In pSS tissue, these conventional acini demonstrated
some dysregulation of AQP5 localization, in line with
other studies of the minor SGs, but maintained their large
cytoplasm:nucleus ratio (22). Acinar clusters in pSS tissue
also contained occasional CK7+ cells. (Figure 1g inset). In
tissue following PD-L1 blockade, AQP5+CK7− acinar clusters
with large cytoplasm:nucleus ratio and apically located AQP5
were not detectable (Figure 1h). The parenchyma post-PD-L1
blockade was instead dominated by mixture of AQP5+CK7−,
AQP5−CK7+, and AQP5+CK7+ cell clusters, whereby AQP5
localization was homogenous throughout the cells and cells
maintained a low cytoplasm:nucleus ratio (Figures 1h,i).
Interestingly, “hybrid” epithelial structures comprising a mixture
of AQP5+ and CK7+ cells comprised 70% of total epithelial
cell clusters (33 structures /mm2; Figures 1h,j). Such hybrid
epithelial structures were also present in sicca control and
pSS tissue, but at much lower frequencies (sicca control 2%
of total IDs, 2 IDs/mm2; pSS 12%, 10/mm2; Figures 1j,k). In
sicca control and pSS tissue, CD4+ and CD8+ T cells were
detected sporadically in SG parenchyma (acinar cells plus IDs;
Figures 1l,m,o,p). Both T cell subsets were present dispersed at
visibly higher frequencies, both in-between and inside epithelial
structures following anti-PD-L1 therapy (Figures 1n,q).
Intercalated Duct-Like Structures Cells Are
Proliferative and Potentially Senescent and
Following Anti-PD-L1 Therapy
In order to probe parenchymal cell dynamics, we immunostained
for the senescence marker p16, and Ki67. In the sicca control and
pSS parotid SGs, Ki67+ proliferating cells were detected at a total
frequency of 6/mm2 and 24/mm2, respectively (Figures 2a,b).
Ninety percent of Ki67+ cells (equal to 5 cells/mm2) were located
in the epithelium (SDs, IDs, and acini) in sicca control tissue,
and 66% (equal to 16 cells/mm2) in pSS tissue (Figure 2d).
In tissue following anti PD-L1 therapy, 275 Ki67+ cells/mm2
were detected, of which 85% (equal to 230 cells /mm2) were
located within the ID-like epithelial structures (Figures 2c,d).
The remaining Ki67+ cells were located in SDs (Figures 2c,d).
p16 can be used to denote senescent cells. p16+ cells
were present at frequencies of 31/mm2 in sicca control tissue
(Figures 2e,h), and were mostly stromal/non epithelial in nature.
We have previously shown that the epithelium of parotid
SGs in the autoimmune disease pSS is likely to contain
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FIGURE 1 | Lack of acinar cells and presence of AQP5+ CK7+ hybrid epithelial structures in the parotid salivary gland following anti-PD-L1 therapy. (a,b,c,e) Ki67
staining in striated ducts of sicca control, pSS and post-anti-PD-L1 therapy tissue. Panels (c,d) (immunostained for high molecular weight cytokeratins (hmwCK) to
mark SD cells, outlined in dashed line) show high resolution of area in inset in (b). (f–h) AQP5 and K7 double immunostaining of sicca control, pSS and
post-anti-PD-L1 therapy tissue. Insets in (f) shows normal K7 and apical AQP5 staining patterns of intercalated ducts and acinar cell, respectively. Inset in (g) show
acinar cell clusters in pSS with occasional CK7+ cell presence. Block arrows in (h) denote AQP5-K7 double-positive cells. (i) Quantification of AQP5 and CK7 cell
content of epithelial cell structures following anti-PD-L1 blockade. (j) Quantification of composition of intercalated duct in sicca control tissue. (k) Quantification of
composition of intercalated ducts in pSS tissue. (l,m) CD4 immunostaining. (o–q) CD8 immunostaining. All scale bars represent 50µm, unless otherwise stated.
elevated numbers of p16+ senescent cells (8). Indeed, p16+
cells were detected in pSS tissue at a total frequency of
37/mm2 (Figures 2f,h). In pSS tissue, p16+ cells were mostly
located in striated ducts, in line with our previous studies
(13/mm2 in SDs, 8/mm2 IDs, 9/mm2 acinar cells; Figures 2f,h).
p16+ cells were present in SG tissue following anti-PD-L1
therapy at a frequency of 51/mm2, higher than both sicca
control and pSS, of which 95% (equal to 48 cells/mm2)
were located in the ID-like epithelial structures described
in Figures 1, 2g,h.
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FIGURE 2 | Hybrid epithelial structures following PD-L1 therapy are proliferative, potentially senescent and express PD-L1. (a–c) Ki67 immunostaining of sicca
control, pSS and post PD-L1 therapy SG tissue. Inset in (c) shows high resolution image of boxed area in main panel. (d) Quantification of Ki67+ epithelial cell types
(sicca control and pSS tissue) or hybrid epithelial structures (str; anti-PD-L1 blockade). (e–g) Immunostaining of sicca control, pSS and post-PD-L1 blockade tissue
for p16. (h) Quantification of frequency of p16+ cells in epithelial cell types (sicca control and pSS tissue), and hybrid epithelial structures (str; anti-PD-L1 tissue). SDs,
(Continued)
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FIGURE 2 | striated ducts; ID, intercalated ducts; Ac, acini clusters. (i) PD-L1 immunostaining in sicca control. (j) PD-L1 immunostaining in pSS tissue. (k) PD-L1
immunostaining in germinal center of pSS SG tissue, showing PD-L1+ lymphocytes. (l) Low resolution microscopy of PD-L1 immunostaining in patient taking
durvalumab. (m) High resolution image of patient taking durvalumab, showing intensely PD-L1+ epithelial structures (white arrow), lightly positive epithelial structures
(black arrow) and positive striated duct cells (block arrow). All scale bars represent 50µM.
Intercalated Duct-Like Structures and
Striated Ducts Express PD-L1 Following
Anti-PD-L1 Therapy
In order to establish if anti-PD-L1 therapy may exert a direct
effect on the SG epithelium, we performed immunostaining
for PD-L1. In sicca control and pSS tissue, no PD-L1+ cells
were present in the SG parenchyma (Figures 2i,j). PD-L1+
presumptive dendritic cells were detected in the germinal
center of pSS tissue (Figure 2k). In tissue following PD-
L1 blockade, unconventional epithelial structures were either
lightly or intensely PD-L1+ (Figures 2l,m). Striated ducts also
demonstrated some PD-L1 positivity (Figure 2m).
Patient Parotid SG Following Prolonged
PD-L1 Inhibitor Use Contains Mostly CD4+
T Cell Infiltrate and Does Not Resemble
pSS Parotid SG Gross Pathology
In order to compare SG histopathological findings (i.e., nature
of sialadentitis, presence of LELs, IgG plasma cells, and germinal
centers) in a patient with sicca following PD-L1 blockade to that
observed in pSS, we performed immunohistochemical staining
for infiltrating lymphoid cells. Sicca control parotid SGs show
dispersed, scarce CD45+ cell presence, no focal CD45+ cell
presence, no focal lymphocytic sialadentitis, no LELs, germinal
centers or IgG plasma cell presence (Figure 3a). These features
were all present in the parotid biopsy of the pSS patient examined
(Figures 3b–g; clinical details in Table 1). CD45+ leukocytes
were present throughout the biopsy post PD-L1 blockade, both
periductally and dispersed between the epithelial cells of the
parenchyma (Figure 3h). The infiltrate was composed of a
majority of CD4+ T cells, in addition to considerable presence of
CD8+ T cells, and a minor contribution to total infiltrate from
CD20+ B cells (Figures 3i–o). CD4+ and CD8+ lymphocytes
present were both diffusely dispersed through the tissue and
focally clustered around the striated ducts, in a similar manner
to pSS (“focal sialadentitis”; Figures 3k,l,n,o). No LELs, germinal
centers or IgG secreting plasma cells were observed in this biopsy
(Figures 1p, 3, Table 1). A focus score of 1.0 was calculated
for the anti-PD-L1 treated patient (the focus score of the pSS
patient was 2.5). Together with the lack of saliva production, this
focus score would lead to classification of this patient post-PD-L1
therapy as suffering from pSS.
DISCUSSION AND CONCLUSIONS
In this case study, we examine parotid SG morphology of a
patient with sicca complaints following anti-PD-L1 therapy,
with particular attention for the epithelium. The most striking
observation was the lack of cells responsible for producing saliva,
namely conventional acinar cell clusters with apically located
AQP5 expression and high cytoplasm:nucleus ratio. Intercalated
duct-like epithelial structures composed of a mixture of
AQP5+CK7−, AQP5−CK7+, and AQP5+CK7+ cells dominated
the parenchyma instead, whereby AQP5 was mislocalized.
Considering the lack of parotid SG function by this patient, these
structures are presumably not capable of saliva production. This
appears to be in contrast with the phenotype of the minor SGs
observed post-ICI use, whereby conventional acinar cells are
still present, suggesting striking differences in the reactionary
abilities between major and minor SGs (3, 5). The phenotype is
also dissimilar to parotid SG dysfunction induced by radiation,
where saliva production is lost immediately following radiation
(as opposed to around 70 days post ICI commencement), and
where tissue will demonstrate both fibrosis and acinar cell cluster
loss (23).
A predominance of CD4+ T cell lymphocytic infiltration
in the parotid SG post-PD-L1 therapy was observed, although
CD8+ T cell presence was also considerable. CD20+ B-cells were
nearly absent. This is in agreement with literature examining
minor SGs, where mostly CD4+ infiltrate was observed (3, 5).
CD4+ and CD8+ T cells were found both focally around but not
inside SDs, in addition to dispersed throughout the tissue. Both
CD4+ and CD8+ T cells also infiltrated the ID-like epithelial
structures post PD-L1 blockade. Interestingly, CD8+ T cells and
CD4+ T cells were also found sporadically in acinar cell clusters
of SG tissue from sicca control and pSS patients, albeit at lower
frequency. These data may suggest that CD8+ cell presence in the
SG parenchyma is detrimental to SG/acinar function, considering
neither sicca control or pSS patient produced normal amounts of
saliva (24).
The phenotype of the SG described in the current case
study raises questions about the sequence of events occurring
in the SG following anti-PD-L1 therapy, and their effect on
acinar cells. PD-L1 expression was greater in the SG parenchyma
after anti-PD-L1 blockade, compared to sicca and pSS control
tissues. Which stimuli originally triggers this increased PD-
L1 expression, and any effect thereafter on SG function of
epithelial PD-L1 interaction with PD-L1 blocking therapeutics
such as durvalumab remains to be clarified. Existing studies
have documented a relationship between PD-L1 expression
and interferon-γ levels (IFNγ), whereby IFNγ has been shown
to increase PD-L1 expression, and PD-L1 expression to be
protective against interferon-γ induced toxicity (25, 26). CD4+
and CD8+ T cells recruited to the SG may be responsible for
the gross alterations in parotid SG dynamics observed, although
which particular CD4+ or CD8+ subsets are responsible will
require phenotyping of the infiltrate. Proliferative (Ki67+) and
potentially senescent (p16+) epithelial cells were detected in this
SG post PD-L1 therapy. The ability to proliferate implies that a
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FIGURE 3 | The histology of a parotid salivary gland following prolonged anti PD-L1 therapy contains focal lymphocytic sialadentitis, but does not resemble the
parotid gland in pSS. (a) CD45 immunohistochemical of sicca control. (b–d) CD45, CD20 and CD3 immunohistochemical staining of a parotid salivary gland from a
(Continued)
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FIGURE 3 | pSS patient. (e) High resolution images of a lymphoepithelial lesion, whereby B cells are seen to invade striated ducts. Through as yet unclear
mechanisms, both B cells and epithelial cells proliferate, and may represent a precursor stadium to MALT lymphomas. White dashed line demarcates boundaries of
original striated duct. Inset box shows CD20+ B cells in between CD20− epithelial cells. (f) High resolution image of a germinal center, indicated by Bcl-6 positivity.
Bcl-6 positive B cells are characteristic of germinal centers. Dashed white line outlines boundaries of germinal center. Inset shows Bcl-6-positive nuclei of B cells. (g)
Double immunohistochemical staining for IgA and IgG classes of antibodies. IgA represents the isotype normally found in mucosal tissues such as the SG (red label).
Where >80% of labeled cells are IgG positive (brown), class switching is assumed to have occurred, such as the present example. (h–n) CD45, CD20, CD8, and CD4
immunohistochemical staining of a parotid salivary gland from patient following prolonged anti-PD-L1 therapy. Insets in (h) shows high resolution of boxed area. (k)
High resolution image of diffuse CD8 immunostaining. (l) High resolution image of focally organized CD8 immunostaining. (n) High resolution image of focally
organized CD4 immunostaining. (o) High resolution image of focal CD8 immunostaining. (p) IgA IgG double immunostaining following prolonged anti-PD-L1 therapy,
showing majority of pink, IgA class antibodies.
SG resident progenitor cell population may have been affected by
anti-PD-L1 therapy, directly or indirectly. The observed skewing
toward unconventional epithelial structures may represent an
attempt by progenitor cells to restore acinar cell balance, which
may have not reached completion.
Sixty percent of patients experiencing lack of saliva production
following checkpoint inhibitor use will progress to fulfill
classification criteria for pSS. Recent studies suggest that small
proportion (7 or 15%, in recent reports) of these patients display
anti-SSA positivity, with the remaining fulfilling classification
criteria owing to positive focus scores (3, 5). SGs affected by pSS,
at least in its advanced stages, are notable for their preponderance
of CD20+ B cells, in addition to germinal center, LELs, and IgG
producing plasma cell presence. These features were not present
in the SG examined here following anti-PD-L1 therapy, in line
with recent reports examining the minor SGs. Thus although
foci are present, the nature of the infiltrate and the pathology
observed are not consistent with the classical SG of a pSS patient
(3, 5). The parotid SG examined in this case does not resemble
that in pSS, histopathologically, despite the presence of anti-SSA
in the serum.
In conclusion, our observations suggest that epithelial tissues
such as the SG can react dramatically to anti-PD-L1 therapy.
Our data supports a recent observation by Warner et al., who
reported that hyposalivation following ICI therapy cannot be
resolved with anti-inflammatory corticosteroid use. These data
imply that the presence of infiltration is not the reason for lack of
SG function observed. According to our data, the SG epithelium
may be grossly dysregulated following PD-L1 blockade (3).
Whether ICI therapy targeting other receptors (anti-CTLA4;
anti-PD-1) also results in loss of acinar structures remains
to be shown. Exhaustive additional studies will be necessary
to comprehend fully the mechanisms behind PD-L1 blockade
induced SG dysfunction, to understand how to affect tumor cell
removal using ICIs with minimal epithelial organ dysfunction.
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